Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.

Click here to watch this now before it’s too late.

BCYC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $438,909.08

Bicycle Therapeutics Insider Trading History Chart

Bicycle Therapeutics Share Price & Price History

^$23.62

▲ +0.54 (2.34%)

As of 05/8/2024 01:00 AM ET

Days: 30 | 90 | 365

The 2024 Gold Rush: Unleashing Market Potential

From Priority Gold | Ad

Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.

Get your free information kit NOW, before it's too late.

Bicycle Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2024	Michael Charles Ferguso Hannay	Insider	Sell	257	$22.49	$5,779.93	22,891
4/3/2024	Kevin Lee	CEO	Sell	3,158	$23.81	$75,191.98	387,270
4/3/2024	Michael Skynner	CTO	Sell	955	$23.81	$22,738.55	94,884
4/3/2024	Nicholas Keen	Insider	Sell	790	$23.81	$18,809.90	62,803
4/3/2024	Travis Alvin Thompson	CAO	Sell	152	$23.81	$3,619.12	23,223
1/3/2024	Kevin Lee	CEO	Sell	8,703	$17.50	$152,302.50	390,428
1/3/2024	Nigel Crockett	Insider	Sell	2,643	$17.50	$46,252.50	48,716
1/3/2024	Travis Alvin Thompson	CAO	Sell	604	$17.50	$10,570.00	23,375
10/3/2023	Alistair Milnes	COO	Sell	442	$20.00	$8,840.00	36,839
10/3/2023	Kevin Lee	CEO	Sell	1,470	$20.00	$29,400.00	322,131
10/3/2023	Nicholas Keen	Insider	Sell	272	$20.00	$5,440.00	38,233
10/3/2023	Travis Alvin Thompson	CAO	Sell	54	$20.00	$1,080.00	7,979
7/3/2023	Kevin Lee	CEO	Sell	1,498	$25.10	$37,599.80	323,601
7/3/2023	Michael Skynner	CTO	Sell	451	$25.10	$11,320.10	70,924
7/3/2023	Nicholas Keen	Insider	Sell	336	$25.10	$8,433.60	38,505
7/3/2023	Travis Alvin Thompson	CAO	Sell	61	$25.10	$1,531.10	8,033
4/3/2023	Kevin Lee	CEO	Sell	1,486	$21.11	$31,369.46	325,099
4/3/2023	Lee Kalowski	CFO	Sell	376	$21.11	$7,937.36	30,309
4/3/2023	Michael Skynner	CTO	Sell	447	$21.11	$9,436.17	71,375
4/3/2023	Nicholas Keen	Insider	Sell	319	$21.11	$6,734.09	38,841
1/3/2023	Kevin Lee	CEO	Sell	6,000	$29.06	$174,360.00	326,585
1/3/2023	Lee Kalowski	CFO	Sell	1,815	$29.06	$52,743.90	30,685
1/3/2023	Nigel Crockett	Insider	Sell	1,801	$29.06	$52,337.06	30,699
12/21/2021	Pierre Legault	Director	Sell	44,537	$57.11	$2,543,508.07
10/18/2021	Kevin Lee	CEO	Sell	49	$60.00	$2,940.00
10/14/2021	Kevin Lee	CEO	Sell	4,631	$60.00	$277,860.00
10/11/2021	Kevin Lee	CEO	Sell	5,000	$53.88	$269,400.00
8/31/2021	Kevin Lee	CEO	Sell	11,225	$36.33	$407,804.25
8/27/2021	Kevin Lee	CEO	Sell	1,808	$36.02	$65,124.16	246,893
8/27/2021	Lee Kalowski	CFO	Sell	7,950	$35.15	$279,442.50	550
8/23/2021	Lee Kalowski	CFO	Sell	7,500	$33.02	$247,650.00	7,500
7/29/2021	Lee Kalowski	CFO	Sell	12,500	$31.51	$393,875.00	12,500
7/26/2021	Kevin Lee	CEO	Sell	100	$36.00	$3,600.00
7/23/2021	Kevin Lee	CEO	Sell	4,782	$36.02	$172,247.64
7/16/2021	Kevin Lee	CEO	Sell	609	$34.00	$20,706.00
7/14/2021	Kevin Lee	CEO	Sell	14,465	$34.34	$496,728.10	256,670
7/13/2021	Kate Bingham	Director	Sell	600	$33.50	$20,100.00
7/13/2021	Nigel Crockett	Insider	Sell	72,701	$32.44	$2,358,420.44	4,331
7/12/2021	Kevin Lee	CEO	Sell	1,936	$32.04	$62,029.44
7/6/2021	Nigel Crockett	Insider	Sell	271	$32.00	$8,672.00	271
5/6/2021	Kevin Lee	CEO	Sell	1,716	$32.14	$55,152.24	256,450

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SEC Filings (Institutional Ownership Changes) for Bicycle Therapeutics (NASDAQ:BCYC)

86.15% of Bicycle Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Bicycle Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	883,105	$21.99M	0.1%	+12.8%	2.940%
5/7/2024	Concurrent Investment Advisors LLC	21,799	$0.54M	0.0%	N/A	0.073%
5/2/2024	PDS Planning Inc	8,450	$0.21M	0.0%	N/A	0.028%
5/1/2024	BNP Paribas Financial Markets	8,834	$0.22M	0.0%	-76.0%	0.029%
4/29/2024	China Universal Asset Management Co. Ltd.	6,859	$0.17M	0.0%	+71.4%	0.023%
4/26/2024	Pinnacle Associates Ltd.	80,090	$1.99M	0.0%	N/A	0.267%
4/23/2024	Fishman Jay A Ltd. MI	9,000	$0.22M	0.0%	-73.9%	0.030%
4/9/2024	Woodstock Corp	24,981	$0.62M	0.1%	+16.3%	0.083%
3/22/2024	PNC Financial Services Group Inc.	7,560	$0.14M	0.0%	N/A	0.025%
2/15/2024	Parkman Healthcare Partners LLC	312,889	$5.66M	0.8%	+155.0%	1.042%
2/15/2024	Comerica Bank	81,850	$1.48M	0.0%	+18,088.9%	0.272%
2/14/2024	First Light Asset Management LLC	1,550,471	$28.03M	2.3%	-25.1%	5.161%
2/14/2024	Bellevue Group AG	20,000	$0.36M	0.0%	-49.0%	0.067%
2/14/2024	Verition Fund Management LLC	740,539	$13.39M	0.1%	-19.2%	2.465%
2/14/2024	Platinum Investment Management Ltd.	362,080	$6.55M	0.3%	+26.8%	1.205%
2/13/2024	Tower Research Capital LLC TRC	2,328	$42K	0.0%	-76.4%	0.008%
2/13/2024	Armistice Capital LLC	1,536,000	$27.77M	0.4%	+53.6%	5.113%
2/9/2024	Westfield Capital Management Co. LP	917,304	$16.59M	0.1%	N/A	3.054%
2/9/2024	Trexquant Investment LP	196,323	$3.55M	0.1%	+177.6%	0.654%
2/7/2024	Jump Financial LLC	77,332	$1.40M	0.0%	+108.6%	0.257%
2/7/2024	BNP Paribas Financial Markets	36,851	$0.67M	0.0%	+10,489.4%	0.123%
2/5/2024	AtonRa Partners	10,435	$0.19M	0.4%	-9.9%	0.035%
2/1/2024	Handelsbanken Fonder AB	139,800	$2.53M	0.0%	+3.9%	0.465%
1/24/2024	Fishman Jay A Ltd. MI	34,500	$0.62M	0.1%	-8.0%	0.115%
1/24/2024	China Universal Asset Management Co. Ltd.	4,001	$72K	0.0%	+489.2%	0.013%
1/8/2024	Woodstock Corp	21,479	$0.39M	0.0%	+4.5%	0.071%
1/5/2024	Exchange Traded Concepts LLC	6,727	$0.12M	0.0%	+34.0%	0.022%
11/22/2023	Polar Capital Holdings Plc	1,011,500	$20.32M	0.1%	+33.2%	3.367%
11/15/2023	RA Capital Management L.P.	800,000	$16.07M	0.3%	N/A	2.663%
11/15/2023	Kennedy Capital Management LLC	156,705	$3.15M	0.1%	+27.2%	0.522%
11/15/2023	Armistice Capital LLC	1,000,000	$20.09M	0.3%	+14.2%	3.329%
11/14/2023	Braidwell LP	1,289,872	$25.91M	0.8%	N/A	4.294%
11/14/2023	Schonfeld Strategic Advisors LLC	52,100	$1.05M	0.0%	-21.2%	0.173%
11/14/2023	Deerfield Management Company L.P. Series C	448,753	$9.02M	0.2%	N/A	1.494%
11/14/2023	Trexquant Investment LP	70,719	$1.42M	0.0%	N/A	0.235%
11/13/2023	Fishman Jay A Ltd. MI	37,500	$0.75M	0.1%	+82.9%	0.125%
11/13/2023	FMR LLC	266,347	$5.35M	0.0%	-7.2%	0.887%
11/13/2023	Maven Securities LTD	22,500	$0.45M	0.0%	N/A	0.075%
11/9/2023	Deutsche Bank AG	96,370	$1.94M	0.0%	+1,051.4%	0.321%
11/7/2023	Alpha DNA Investment Management LLC	27,957	$0.56M	0.2%	N/A	0.093%
11/7/2023	Jump Financial LLC	37,067	$0.75M	0.0%	+104.1%	0.123%
11/3/2023	Platinum Investment Management Ltd.	285,479	$5.74M	0.2%	N/A	0.950%
10/27/2023	TD Asset Management Inc	81,786	$1.64M	0.0%	+246.8%	0.272%
10/25/2023	BluePath Capital Management LLC	1,534	$31K	0.0%	N/A	0.005%
10/25/2023	AtonRa Partners	11,588	$0.23M	0.5%	-18.5%	0.039%
10/20/2023	Harbor Capital Advisors Inc.	24,210	$0.49M	0.1%	+15.0%	0.081%
10/17/2023	Mach 1 Financial Group LLC	24,701	$0.50M	0.2%	N/A	0.082%
10/11/2023	AE Wealth Management LLC	24,773	$0.50M	0.0%	N/A	0.082%
8/14/2023	Bellevue Group AG	25,000	$0.64M	0.0%	-53.0%	0.083%
8/14/2023	UniSuper Management Pty Ltd	113,458	$2.90M	0.0%	N/A	0.378%
8/14/2023	Polar Capital Holdings Plc	759,500	$19.38M	0.1%	-24.8%	2.528%
8/14/2023	Prelude Capital Management LLC	9,061	$0.23M	0.0%	-28.3%	0.030%
8/11/2023	Natixis	2,775	$70K	0.0%	-18.4%	0.009%
8/11/2023	ExodusPoint Capital Management LP	111,973	$2.86M	0.0%	-8.8%	0.373%
8/10/2023	Tekla Capital Management LLC	44,338	$1.13M	0.0%	-50.0%	0.148%
8/8/2023	Candriam S.C.A.	1,273,261	$32.49M	0.2%	-2.3%	4.239%
8/2/2023	Handelsbanken Fonder AB	134,500	$3.43M	0.0%	+2.0%	0.448%
7/25/2023	DekaBank Deutsche Girozentrale	30,000	$0.72M	0.0%	+127.3%	0.100%
7/20/2023	Exchange Traded Concepts LLC	5,276	$0.14M	0.0%	N/A	0.018%
7/18/2023	AtonRa Partners	14,219	$0.36M	0.6%	-6.3%	0.047%
7/11/2023	Harbor Capital Advisors Inc.	21,045	$0.54M	0.1%	+10.0%	0.070%
7/7/2023	Woodstock Corp	20,553	$0.53M	0.1%	+10.3%	0.068%
6/1/2023	Prelude Capital Management LLC	12,634	$0.27M	0.0%	N/A	0.059%
5/16/2023	First Light Asset Management LLC	699,328	$14.88M	1.3%	+0.4%	3.282%
5/16/2023	Armistice Capital LLC	736,000	$15.66M	0.2%	N/A	3.455%
5/15/2023	Logos Global Management LP	750,000	$15.95M	2.3%	-47.7%	3.520%
5/15/2023	Rubric Capital Management LP	205,423	$4.37M	0.1%	N/A	0.964%
5/15/2023	Sio Capital Management LLC	967,347	$20.58M	10.2%	+41.5%	4.540%
5/12/2023	Candriam S.C.A.	1,303,211	$25.51M	0.2%	+10.9%	6.117%
5/11/2023	ExodusPoint Capital Management LP	122,781	$2.61M	0.0%	+17.1%	0.576%
5/5/2023	AtonRa Partners	15,169	$0.32M	0.5%	-11.1%	0.071%
5/3/2023	Jump Financial LLC	37,737	$0.80M	0.0%	+410.0%	0.177%
4/26/2023	Harbor Capital Advisors Inc.	19,132	$0.41M	0.1%	-20.8%	0.090%
4/6/2023	Woodstock Corp	18,630	$0.40M	0.1%	+25.5%	0.087%
2/15/2023	First Light Asset Management LLC	696,432	$20.61M	1.9%	-1.2%	2.346%
2/14/2023	Verition Fund Management LLC	380,849	$11.27M	0.2%	+9.3%	1.283%
2/14/2023	Pura Vida Investments LLC	239,015	$7.08M	0.4%	+12.1%	0.805%
2/13/2023	ExodusPoint Capital Management LP	104,866	$3.10M	0.0%	+33.3%	0.353%
2/7/2023	Handelsbanken Fonder AB	131,800	$3.90M	0.0%	+1.4%	0.444%
2/7/2023	TD Asset Management Inc	23,586	$0.70M	0.0%	+51.3%	0.079%
2/2/2023	AtonRa Partners	17,067	$0.51M	0.6%	-21.0%	0.057%
1/20/2023	Harbor Capital Advisors Inc.	24,147	$0.72M	0.7%	-47.1%	0.081%
1/17/2023	Twelve Points Wealth Management LLC	7,200	$0.21M	0.1%	N/A	0.024%
11/15/2022	Tybourne Capital Management HK Ltd.	1,041,331	$24.22M	2.3%	-9.8%	3.507%
11/15/2022	Pura Vida Investments LLC	213,121	$4.96M	0.3%	+16.4%	0.718%
11/15/2022	Parkman Healthcare Partners LLC	81,364	$1.89M	0.5%	+34.7%	0.274%
11/15/2022	Logos Global Management LP	2,000,000	$46.52M	5.7%	+17.6%	6.736%
11/15/2022	First Light Asset Management LLC	704,721	$16.39M	1.7%	+0.1%	2.374%
11/15/2022	Bellevue Group AG	98,100	$2.28M	0.0%	+16.2%	0.330%
11/14/2022	Point72 Asset Management L.P.	1,255,418	$29.20M	0.1%	-13.1%	4.230%
11/14/2022	Verition Fund Management LLC	348,513	$8.11M	0.1%	-12.7%	1.174%
11/14/2022	Samlyn Capital LLC	1,294,085	$30.10M	0.6%	+24.4%	4.361%
11/14/2022	AXA S.A.	410,640	$9.55M	0.0%	-11.3%	1.384%
11/14/2022	UBS Oconnor LLC	67,625	$1.57M	0.0%	+17.4%	0.228%
11/10/2022	ExodusPoint Capital Management LP	78,682	$1.83M	0.0%	-56.8%	0.265%
11/8/2022	Allianz Asset Management GmbH	15,200	$0.35M	0.0%	-82.0%	0.051%
11/2/2022	Victory Capital Management Inc.	35,857	$0.83M	0.0%	+7.3%	0.121%
11/1/2022	Tekla Capital Management LLC	88,676	$2.06M	0.1%	+341.9%	0.299%
10/28/2022	Harbor Capital Advisors Inc.	45,667	$1.06M	1.0%	-10.5%	0.154%
10/25/2022	Cutler Group LLC CA	2,100	$48K	0.0%	-19.2%	0.007%

Data available starting January 2016

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $23.62

$23.00

$25.00

50 Day Range

MA: $23.87

$21.82

$25.85

52 Week Range

Now: $23.62

$12.54

$28.91

Volume

227,970 shs

Average Volume

371,352 shs

Market Capitalization

$709.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Who are the company insiders with the largest holdings of Bicycle Therapeutics?: Bicycle Therapeutics' top insider investors include:
Kevin Lee (CEO)
Michael Skynner (CTO)
Nicholas Keen (Insider)
Nigel Crockett (Insider)
Alistair Milnes (COO)
Lee Kalowski (CFO)
Travis Alvin Thompson (CAO)
Michael Charles Ferguso Hannay (Insider)
Learn More about top insider investors at Bicycle Therapeutics.
Who are the major institutional investors of Bicycle Therapeutics?: Bicycle Therapeutics' top institutional investors include:
BNP PARIBAS ASSET MANAGEMENT Holding S.A. — 2.94%
Pinnacle Associates Ltd. — 0.27%
Woodstock Corp — 0.08%
Concurrent Investment Advisors LLC — 0.07%
Fishman Jay A Ltd. MI — 0.03%
BNP Paribas Financial Markets — 0.03%
Learn More about top institutional investors of Bicycle Therapeutics stock.
Which major investors are selling Bicycle Therapeutics stock?: During the last quarter, BCYC stock was sold by these institutional investors:
BNP Paribas Financial Markets
Fishman Jay A Ltd. MI
During the previous year, company insiders that have sold Bicycle Therapeutics company stock include:
Kevin Lee (CEO)
Michael Skynner (CTO)
Nicholas Keen (Insider)
Nigel Crockett (Insider)
Alistair Milnes (COO)
Lee Kalowski (CFO)
Travis Alvin Thompson (CAO)
Learn More investors selling Bicycle Therapeutics stock.
Which major investors are buying Bicycle Therapeutics stock?: During the previous quarter, BCYC stock was acquired by institutional investors including:
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
Pinnacle Associates Ltd.
Concurrent Investment Advisors LLC
PDS Planning Inc
Woodstock Corp
China Universal Asset Management Co. Ltd.
Simplex Trading LLC

How Biden has already won 2024

From Porter & Company | Ad